Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03597347 · ClinicalTrials.gov registry record · Phase 2
Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection
A Phase 2 study, sponsored by Savara.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT03597347 is a Phase 2 study that was terminated before completion, run by Savara. The registered enrollment target is 14 participants.
The verdict
NCT03597347, a Phase 2 study, was terminated before completion, sponsored by Savara.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
A study to evaluate the efficacy of inhaled molgramostim administered open-label to adult cystic fibrosis (CF) subjects with chronic pulmonary nontuberculous mycobacterial (NTM) infection, with or without ongoing antimycobacterial guideline based combination therapy.
Interventions
- DEVICE PARI eFlow nebulizer system
- DRUG Molgramostim nebulizer solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-06-20 |
| Est. Completion | 2020-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03597347
The ClinicalTrials.gov registry entry for NCT03597347 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Savara, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PARI eFlow nebulizer system is the first listed.
NCT03597347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03597347 about?
NCT03597347 is a clinical study titled "Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection". A study to evaluate the efficacy of inhaled molgramostim administered open-label to adult cystic fibrosis (CF) subjects with chronic pulmonary nontuberculous mycobacterial (NTM) infection, with or without ongoing antimycobacterial guideline based combination therapy.
What is the current status of trial NCT03597347?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2019-06-20. Estimated completion is 2020-10-02.
What interventions are being tested in trial NCT03597347?
The interventions under investigation include: PARI eFlow nebulizer system (DEVICE), Molgramostim nebulizer solution (DRUG).
Who is sponsoring clinical trial NCT03597347?
This trial is sponsored by Savara, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.